The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Circulating Tumor Cell Diagnostics-Global Market Insights and Sales Trends 2025
Synopsis
Circulating tumor cells are significantly useful in determining the status of disease progression rate and projection of therapy needed for tumor eradication. Further development of various tumor markers that can be used along with companion diagnostics to diagnose or monitor various forms of cancer are expected to boost usage rates of CTC tests in the coming years.
Circulating tumor cell detection test possesses the ability to detect, quantify, and analyze tumor cells in the blood of cancer patients. It includes enrichment, detection and analysis of the detected circulating tumor cells. Circulating tumor cells tests are applicable in the characterization of tumor cells through biochemical marker analysis. CTC isolation, detection, and molecular characterization systems find investigational application in prostate, breast, colon, head, neck, skin, lung, and pancreatic cancer
Growing incidences oncology diseases and the introduction of novel biotechnological methods that enable the isolation and quantitation of circulating tumor cells. Furthermore, other factors like early disease diagnosis, cost savings on multiple treatments, drug safety, patient compliance, and optimization of therapies are attributive for rising demand for the preventive medicine, thus influencing the demand for CTC tests.
On course of the forecast period it is expected that over 150 companion diagnostic on-label combinations and a range of personalized therapeutic drugs under clinical trials and development pipelines based on companion diagnostics. The level of adoption of companion diagnostics is expected to significantly increase after these obtain complete FDA approval and are commercialized fully.
The global Circulating Tumor Cell Diagnostics market size is expected to reach US$ 9239.7 million by 2029, growing at a CAGR of 9.2% from 2023 to 2029. The market is mainly driven by the significant applications of Circulating Tumor Cell Diagnostics in various end use industries. The expanding demands from the Tumorigenesis research, EMT biomarkers development, Cancer stem cell research and Others, are propelling Circulating Tumor Cell Diagnostics market. CTC Enrichment, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the CTC Detection segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Circulating Tumor Cell Diagnostics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Circulating Tumor Cell Diagnostics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Circulating Tumor Cell Diagnostics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Circulating Tumor Cell Diagnostics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Circulating Tumor Cell Diagnostics covered in this report include Janssen Diagnostics, Advanced Cell Diagnostics, Aviva Biosciences, Biocept Inc, Biofluidica Inc., CellTraffix Inc., Clearbridge BioMedics Pte Ltd, Epic Sciences Inc. and Fluxion Biosciences Inc., etc.
The global Circulating Tumor Cell Diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Janssen Diagnostics
Advanced Cell Diagnostics
Aviva Biosciences
Biocept Inc
Biofluidica Inc.
CellTraffix Inc.
Clearbridge BioMedics Pte Ltd
Epic Sciences Inc.
Fluxion Biosciences Inc.
ScreenCell
Silicon Biosystems
Sysmex Corporation
Greiner Bio-One GmbH
AdnaGen AG
Apocell Inc
Biocep Ltd
Canopus Bioscience Ltd
Creatv Microtech Inc
Ikonisys Inc
IV Diagnostics Inc
Miltenyi Biotech GmbH
Nanostring Technologies Inc
Rarecells Diagnostics.
Vitatex Inc
Global Circulating Tumor Cell Diagnostics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Circulating Tumor Cell Diagnostics market, Segment by Type:
CTC Enrichment
CTC Detection
CTC Analysis
Global Circulating Tumor Cell Diagnostics market, by Application
Tumorigenesis research
EMT biomarkers development
Cancer stem cell research
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Circulating Tumor Cell Diagnostics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Circulating tumor cells are significantly useful in determining the status of disease progression rate and projection of therapy needed for tumor eradication. Further development of various tumor markers that can be used along with companion diagnostics to diagnose or monitor various forms of cancer are expected to boost usage rates of CTC tests in the coming years.
Circulating tumor cell detection test possesses the ability to detect, quantify, and analyze tumor cells in the blood of cancer patients. It includes enrichment, detection and analysis of the detected circulating tumor cells. Circulating tumor cells tests are applicable in the characterization of tumor cells through biochemical marker analysis. CTC isolation, detection, and molecular characterization systems find investigational application in prostate, breast, colon, head, neck, skin, lung, and pancreatic cancer
Growing incidences oncology diseases and the introduction of novel biotechnological methods that enable the isolation and quantitation of circulating tumor cells. Furthermore, other factors like early disease diagnosis, cost savings on multiple treatments, drug safety, patient compliance, and optimization of therapies are attributive for rising demand for the preventive medicine, thus influencing the demand for CTC tests.
On course of the forecast period it is expected that over 150 companion diagnostic on-label combinations and a range of personalized therapeutic drugs under clinical trials and development pipelines based on companion diagnostics. The level of adoption of companion diagnostics is expected to significantly increase after these obtain complete FDA approval and are commercialized fully.
The global Circulating Tumor Cell Diagnostics market size is expected to reach US$ 9239.7 million by 2029, growing at a CAGR of 9.2% from 2023 to 2029. The market is mainly driven by the significant applications of Circulating Tumor Cell Diagnostics in various end use industries. The expanding demands from the Tumorigenesis research, EMT biomarkers development, Cancer stem cell research and Others, are propelling Circulating Tumor Cell Diagnostics market. CTC Enrichment, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the CTC Detection segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Circulating Tumor Cell Diagnostics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Circulating Tumor Cell Diagnostics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Circulating Tumor Cell Diagnostics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Circulating Tumor Cell Diagnostics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Circulating Tumor Cell Diagnostics covered in this report include Janssen Diagnostics, Advanced Cell Diagnostics, Aviva Biosciences, Biocept Inc, Biofluidica Inc., CellTraffix Inc., Clearbridge BioMedics Pte Ltd, Epic Sciences Inc. and Fluxion Biosciences Inc., etc.
The global Circulating Tumor Cell Diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Janssen Diagnostics
Advanced Cell Diagnostics
Aviva Biosciences
Biocept Inc
Biofluidica Inc.
CellTraffix Inc.
Clearbridge BioMedics Pte Ltd
Epic Sciences Inc.
Fluxion Biosciences Inc.
ScreenCell
Silicon Biosystems
Sysmex Corporation
Greiner Bio-One GmbH
AdnaGen AG
Apocell Inc
Biocep Ltd
Canopus Bioscience Ltd
Creatv Microtech Inc
Ikonisys Inc
IV Diagnostics Inc
Miltenyi Biotech GmbH
Nanostring Technologies Inc
Rarecells Diagnostics.
Vitatex Inc
Global Circulating Tumor Cell Diagnostics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Circulating Tumor Cell Diagnostics market, Segment by Type:
CTC Enrichment
CTC Detection
CTC Analysis
Global Circulating Tumor Cell Diagnostics market, by Application
Tumorigenesis research
EMT biomarkers development
Cancer stem cell research
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Circulating Tumor Cell Diagnostics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Circulating Tumor Cell Diagnostics
1.1 Circulating Tumor Cell Diagnostics Market Overview
1.1.1 Circulating Tumor Cell Diagnostics Product Scope
1.1.2 Circulating Tumor Cell Diagnostics Market Status and Outlook
1.2 Global Circulating Tumor Cell Diagnostics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Circulating Tumor Cell Diagnostics Market Size by Region (2018-2029)
1.4 Global Circulating Tumor Cell Diagnostics Historic Market Size by Region (2018-2023)
1.5 Global Circulating Tumor Cell Diagnostics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Circulating Tumor Cell Diagnostics Market Size (2018-2029)
1.6.1 North America Circulating Tumor Cell Diagnostics Market Size (2018-2029)
1.6.2 Europe Circulating Tumor Cell Diagnostics Market Size (2018-2029)
1.6.3 Asia-Pacific Circulating Tumor Cell Diagnostics Market Size (2018-2029)
1.6.4 Latin America Circulating Tumor Cell Diagnostics Market Size (2018-2029)
1.6.5 Middle East & Africa Circulating Tumor Cell Diagnostics Market Size (2018-2029)
2 Circulating Tumor Cell Diagnostics Market by Type
2.1 Introduction
2.1.1 CTC Enrichment
2.1.2 CTC Detection
2.1.3 CTC Analysis
2.2 Global Circulating Tumor Cell Diagnostics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Circulating Tumor Cell Diagnostics Historic Market Size by Type (2018-2023)
2.2.2 Global Circulating Tumor Cell Diagnostics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Circulating Tumor Cell Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Circulating Tumor Cell Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Circulating Tumor Cell Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Circulating Tumor Cell Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Circulating Tumor Cell Diagnostics Revenue Breakdown by Type (2018-2029)
3 Circulating Tumor Cell Diagnostics Market Overview by Application
3.1 Introduction
3.1.1 Tumorigenesis research
3.1.2 EMT biomarkers development
3.1.3 Cancer stem cell research
3.1.4 Others
3.2 Global Circulating Tumor Cell Diagnostics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Circulating Tumor Cell Diagnostics Historic Market Size by Application (2018-2023)
3.2.2 Global Circulating Tumor Cell Diagnostics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Circulating Tumor Cell Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Circulating Tumor Cell Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Circulating Tumor Cell Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Circulating Tumor Cell Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Circulating Tumor Cell Diagnostics Revenue Breakdown by Application (2018-2029)
4 Circulating Tumor Cell Diagnostics Competition Analysis by Players
4.1 Global Circulating Tumor Cell Diagnostics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Circulating Tumor Cell Diagnostics as of 2022)
4.3 Date of Key Players Enter into Circulating Tumor Cell Diagnostics Market
4.4 Global Top Players Circulating Tumor Cell Diagnostics Headquarters and Area Served
4.5 Key Players Circulating Tumor Cell Diagnostics Product Solution and Service
4.6 Competitive Status
4.6.1 Circulating Tumor Cell Diagnostics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Janssen Diagnostics
5.1.1 Janssen Diagnostics Profile
5.1.2 Janssen Diagnostics Main Business
5.1.3 Janssen Diagnostics Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.1.4 Janssen Diagnostics Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.1.5 Janssen Diagnostics Recent Developments
5.2 Advanced Cell Diagnostics
5.2.1 Advanced Cell Diagnostics Profile
5.2.2 Advanced Cell Diagnostics Main Business
5.2.3 Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.2.4 Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.2.5 Advanced Cell Diagnostics Recent Developments
5.3 Aviva Biosciences
5.3.1 Aviva Biosciences Profile
5.3.2 Aviva Biosciences Main Business
5.3.3 Aviva Biosciences Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.3.4 Aviva Biosciences Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.3.5 Biocept Inc Recent Developments
5.4 Biocept Inc
5.4.1 Biocept Inc Profile
5.4.2 Biocept Inc Main Business
5.4.3 Biocept Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.4.4 Biocept Inc Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.4.5 Biocept Inc Recent Developments
5.5 Biofluidica Inc.
5.5.1 Biofluidica Inc. Profile
5.5.2 Biofluidica Inc. Main Business
5.5.3 Biofluidica Inc. Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.5.4 Biofluidica Inc. Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.5.5 Biofluidica Inc. Recent Developments
5.6 CellTraffix Inc.
5.6.1 CellTraffix Inc. Profile
5.6.2 CellTraffix Inc. Main Business
5.6.3 CellTraffix Inc. Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.6.4 CellTraffix Inc. Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.6.5 CellTraffix Inc. Recent Developments
5.7 Clearbridge BioMedics Pte Ltd
5.7.1 Clearbridge BioMedics Pte Ltd Profile
5.7.2 Clearbridge BioMedics Pte Ltd Main Business
5.7.3 Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.7.4 Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.7.5 Clearbridge BioMedics Pte Ltd Recent Developments
5.8 Epic Sciences Inc.
5.8.1 Epic Sciences Inc. Profile
5.8.2 Epic Sciences Inc. Main Business
5.8.3 Epic Sciences Inc. Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.8.4 Epic Sciences Inc. Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.8.5 Epic Sciences Inc. Recent Developments
5.9 Fluxion Biosciences Inc.
5.9.1 Fluxion Biosciences Inc. Profile
5.9.2 Fluxion Biosciences Inc. Main Business
5.9.3 Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.9.4 Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.9.5 Fluxion Biosciences Inc. Recent Developments
5.10 ScreenCell
5.10.1 ScreenCell Profile
5.10.2 ScreenCell Main Business
5.10.3 ScreenCell Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.10.4 ScreenCell Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.10.5 ScreenCell Recent Developments
5.11 Silicon Biosystems
5.11.1 Silicon Biosystems Profile
5.11.2 Silicon Biosystems Main Business
5.11.3 Silicon Biosystems Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.11.4 Silicon Biosystems Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.11.5 Silicon Biosystems Recent Developments
5.12 Sysmex Corporation
5.12.1 Sysmex Corporation Profile
5.12.2 Sysmex Corporation Main Business
5.12.3 Sysmex Corporation Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.12.4 Sysmex Corporation Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.12.5 Sysmex Corporation Recent Developments
5.13 Greiner Bio-One GmbH
5.13.1 Greiner Bio-One GmbH Profile
5.13.2 Greiner Bio-One GmbH Main Business
5.13.3 Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.13.4 Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.13.5 Greiner Bio-One GmbH Recent Developments
5.14 AdnaGen AG
5.14.1 AdnaGen AG Profile
5.14.2 AdnaGen AG Main Business
5.14.3 AdnaGen AG Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.14.4 AdnaGen AG Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.14.5 AdnaGen AG Recent Developments
5.15 Apocell Inc
5.15.1 Apocell Inc Profile
5.15.2 Apocell Inc Main Business
5.15.3 Apocell Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.15.4 Apocell Inc Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.15.5 Apocell Inc Recent Developments
5.16 Biocep Ltd
5.16.1 Biocep Ltd Profile
5.16.2 Biocep Ltd Main Business
5.16.3 Biocep Ltd Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.16.4 Biocep Ltd Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.16.5 Biocep Ltd Recent Developments
5.17 Canopus Bioscience Ltd
5.17.1 Canopus Bioscience Ltd Profile
5.17.2 Canopus Bioscience Ltd Main Business
5.17.3 Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.17.4 Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.17.5 Canopus Bioscience Ltd Recent Developments
5.18 Creatv Microtech Inc
5.18.1 Creatv Microtech Inc Profile
5.18.2 Creatv Microtech Inc Main Business
5.18.3 Creatv Microtech Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.18.4 Creatv Microtech Inc Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.18.5 Creatv Microtech Inc Recent Developments
5.19 Ikonisys Inc
5.19.1 Ikonisys Inc Profile
5.19.2 Ikonisys Inc Main Business
5.19.3 Ikonisys Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.19.4 Ikonisys Inc Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.19.5 Ikonisys Inc Recent Developments
5.20 IV Diagnostics Inc
5.20.1 IV Diagnostics Inc Profile
5.20.2 IV Diagnostics Inc Main Business
5.20.3 IV Diagnostics Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.20.4 IV Diagnostics Inc Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.20.5 IV Diagnostics Inc Recent Developments
5.21 Miltenyi Biotech GmbH
5.21.1 Miltenyi Biotech GmbH Profile
5.21.2 Miltenyi Biotech GmbH Main Business
5.21.3 Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.21.4 Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.21.5 Miltenyi Biotech GmbH Recent Developments
5.22 Nanostring Technologies Inc
5.22.1 Nanostring Technologies Inc Profile
5.22.2 Nanostring Technologies Inc Main Business
5.22.3 Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.22.4 Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.22.5 Nanostring Technologies Inc Recent Developments
5.23 Rarecells Diagnostics.
5.23.1 Rarecells Diagnostics. Profile
5.23.2 Rarecells Diagnostics. Main Business
5.23.3 Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.23.4 Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.23.5 Rarecells Diagnostics. Recent Developments
5.24 Vitatex Inc
5.24.1 Vitatex Inc Profile
5.24.2 Vitatex Inc Main Business
5.24.3 Vitatex Inc Circulating Tumor Cell Diagnostics Products, Services and Solutions
5.24.4 Vitatex Inc Circulating Tumor Cell Diagnostics Revenue (US$ Million) & (2018-2023)
5.24.5 Vitatex Inc Recent Developments
6 North America
6.1 North America Circulating Tumor Cell Diagnostics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Circulating Tumor Cell Diagnostics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Circulating Tumor Cell Diagnostics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Circulating Tumor Cell Diagnostics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Circulating Tumor Cell Diagnostics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Circulating Tumor Cell Diagnostics Market Dynamics
11.1 Circulating Tumor Cell Diagnostics Industry Trends
11.2 Circulating Tumor Cell Diagnostics Market Drivers
11.3 Circulating Tumor Cell Diagnostics Market Challenges
11.4 Circulating Tumor Cell Diagnostics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
